Figure S1. Diagnostic values of 7-AABs alone or in combination with non-specific tumor markers for patients with early-stage malignant lung nodules. (A) The specificity, sensitivity, PPV and NPV of 7-AABs, 7-AABs + HSP90a, 7-AABs + CEA, 7-AABs + CYFRA21-1, 7-AABs + CA199 and 7-AABs + CA125. (B) The RR of 7-AABs, 7-AABs + HSP90a, 7-AABs + CEA, 7-AABs + CYFRA21-1, 7-AABs + CA199 and 7-AABs + CA125. (C) Diagnostic efficiency was assessed using the ROC curve. The results of 7-AABs, 7-AABs + HSP90a, 7-AABs + CEA, 7-AABs + CYFRA21-1, 7-AABs + CA199 and 7-AABs + CA125 were identical to the ROC analysis using the overlapped data. 7-AABs, seven lung cancer-related autoantibodies; ROC, receiver operating characteristic; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin fragment antigen 21-1; CA199, carbohydrate antigen 199; CA125, carbohydrate antigen 125; HSP90a, heat shock protein 90a; PPV, positive predictive value; NPV, negative predictive value; RR, relative risk; CI, confidence interval
Figure S1. Diagnostic values of 7-AABs alone or in combination with non-specific tumor markers for patients with early-stage malignant lung nodules. (A) The specificity, sensitivity, PPV and NPV of 7-AABs, 7-AABs + HSP90a, 7-AABs + CEA, 7-AABs + CYFRA21-1, 7-AABs + CA199 and 7-AABs + CA125. (B) The RR of 7-AABs, 7-AABs + HSP90a, 7-AABs + CEA, 7-AABs + CYFRA21-1, 7-AABs + CA199 and 7-AABs + CA125. (C) Diagnostic efficiency was assessed using the ROC curve. The results of 7-AABs, 7-AABs + HSP90a, 7-AABs + CEA, 7-AABs + CYFRA21-1, 7-AABs + CA199 and 7-AABs + CA125 were identical to the ROC analysis using the overlapped data. 7-AABs, seven lung cancer-related autoantibodies; ROC, receiver operating characteristic; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin fragment antigen 21-1; CA199, carbohydrate antigen 199; CA125, carbohydrate antigen 125; HSP90a, heat shock protein 90a; PPV, positive predictive value; NPV, negative predictive value; RR, relative risk; CI, confidence interval